CAR-T cells (for T cells carrying a chimeric receptor) are involved in gene therapies. These new treatments are currently used in onco-hematology. The cells are made from the patient's own T-lymphocytes. When genetically modified and reinjected, they are capable of specifically recognizing and destroying cancer cells after binding to the tumor antigen by releasing a mixture of cytokines and pro-inflammatory chemokines.
This literature review, based on several scientific publications, focuses on the activation of CAR-T cells in vitro, monitored by using our homogeneous technologies such as AlphaLISA® and HTRF®. These methods are simple, sensitive, and robust, while consuming a minimum of samples and providing results faster than ELISA tests.
See below the different points monitored by our technologies in this literature review:
- Measurement of cell proliferation and cytokine release
- Cytotoxicity tests: DELFIA Eu TDA in CAR-T co-culture
- Cytotoxicity percentage measurement of CD19-expressing target cell lines
- Measurement of IFN concentrations-γ
